# Avantor, Inc.: Form 10-Q for the period ended Mar 31, 2022

- Company: [Avantor, Inc.](/companies/avtr.md) (CIK 1722482)
- Form: 10-Q
- Filed: 2022-04-29
- Accepted by EDGAR: Apr 29, 2022, 08:37 ET
- Period: 2022-03-31
- Accession: 0001722482-22-000114
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1722482/000172248222000114/avtr-20220331.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1722482/000172248222000114/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2022-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2022-01-01 to 2022-03-31 | $1.95bn | us-gaap:Revenues |
| Cost of revenue | 3 months, 2022-01-01 to 2022-03-31 | $1.26bn | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2022-01-01 to 2022-03-31 | $689.9m | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months, 2022-01-01 to 2022-03-31 | $382.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2022-01-01 to 2022-03-31 | $307.0m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2022-01-01 to 2022-03-31 | $64.8m | us-gaap:InterestExpense |
| Income tax | 3 months, 2022-01-01 to 2022-03-31 | $51.4m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2022-01-01 to 2022-03-31 | $190.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2022-01-01 to 2022-03-31 | $0.28 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2022-01-01 to 2022-03-31 | $0.29 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2022-01-01 to 2022-03-31 | 681,300,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months, 2022-01-01 to 2022-03-31 | $152.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2022-01-01 to 2022-03-31 | $24.5m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2022-03-31 | $283.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2022-03-31 | $2.61bn | us-gaap:AssetsCurrent |
| Total assets | at 2022-03-31 | $13.84bn | us-gaap:Assets |
| Current liabilities | at 2022-03-31 | $1.45bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2022-03-31 | $9.48bn | us-gaap:Liabilities |
| Long-term debt | at 2022-03-31 | $6.82bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2022-03-31 | $44.7m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2022-03-31 | $4.36bn | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 22,843 characters.

*In addition to historical financial information, this discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our results may differ materially from those contained in or implied by any forward-looking statements. You should carefully read “Cautionary factors regarding forward-looking statements” for additional information.*

### Basis of presentation

This discussion should be read in conjunction with the accompanying condensed consolidated financial statements and notes. Pursuant to SEC rules for reports covering interim periods, we have prepared this discussion and analysis to enable you to assess material changes in our financial condition and results of operations since December 31, 2021, the date of our Annual Report. Therefore, we encourage you to read this discussion and analysis in conjunction with the Annual Report.

### Overview

We are a leading global provider of mission critical products and services to customers in the biopharmaceutical, healthcare, education & government and advanced technologies & applied materials industries. We have global operations and an extensive product portfolio. We strive to enable customer success through innovation, cGMP manufacturing and comprehensive service offerings. The depth and breadth of our portfolio provides our customers a comprehensive range of products and services and allows us to create customized and integrated solutions for our customers.

During the three months ended March 31, 2022 we recorded net sales of $1,950.4 million, net income of $190.4 million and Adjusted EBITDA of $423.1 million. Net sales increased by 9.2%, which included 5.1% organic growth compared to the same period in 2021. See “Reconciliations of non-GAAP measures” for a reconciliation of net income to Adjusted EBITDA and “Results of operations” for a reconciliation of net sales growth to organic net sales growth.

### Factors and current trends affecting our business and results of operations

The following updates the factors and current trends disclosed in the Annual Report. These updates could affect our performance and financial condition in future periods.

### Our results are impacted by acquisitions

We completed the acquisition of Masterflex, Ritter GmbH, and RIM Bio in 2021. Masterflex is a leading global manufacturer of peristaltic pumps and aseptic single-use fluid transfer technologies. Ritter GmbH's current business is focused on performing life sciences research and supplying diagnostic system providers, liquid handling OEMs and end-users with robotic fluid handling tips, plates, and other consumables. RIM Bio is a China-based single-use bioprocess bag manufacturer. RIM Bio's current business provides a complete range of single-use 2D bags, 3D bags, tank liners, bag assemblies and multi-bag manifolds used in the manufacturing of biologics including monoclonal antibodies (mAbs), vaccines, cell and gene therapies, and recombinant proteins.

### Our results continue to be impacted by the ongoing global coronavirus outbreak

The results for each of our three regions continue to be impacted by the COVID-19 pandemic for the three months ended March 31, 2022, as described further in the “Results of operations” section below.

For a discussion of the impact of the COVID-19 pandemic and associated economic disruptions, and the actual operational and financial impacts that we experienced through December 31, 2021, see “Part II—Item 7—Management's discussion and analysis of financial condition and results of operations” in the Annual Report. For additional discussion of the potential impact of the COVID-19 pandemic and associated economic disruptions to the Company, see “The COVID-19 pandemic has adversely impacted, and continues to pose risks to, our business, operating results, cash flows and/or financial condition, the nature and extent of which could be material.” included in “Part I—Item 1A—Risk factors” in the Annual Report.

### We have been impacted by supply chain constraints and inflationary pressures

We have experienced challenges in sourcing certain products and raw materials as a result of global supply chain disruptions and have experienced inflationary pressures across all of our cost categories. While we have implemented pricing and productivity measures to combat these pressures, they may impact our results.

### Key indicators of performance and financial condition

To evaluate our performance, we monitor a number of key indicators including certain non-GAAP financial measurements that we believe are useful to investors, creditors and others in assessing our performance. These measurements should not be considered in isolation or as a substitute for reported GAAP results because they may include or exclude certain items as compared to similar GAAP-based measurements, and such measurements may not be comparable to similarly-titled measurements reported by other companies. Rather, these measurements should be considered as an additional way of viewing aspects of our operations that provide a more complete understanding of our business.

The key indicators that we monitor are as follows:

- ***Net sales, gross margin, operating income*** and ***net income or loss***. These measures are discussed in the section entitled “Results of operations;”
- ***Organic net sales growth,*** which is a non-GAAP measure discussed in the section entitled “Results of operations.” Organic net sales growth eliminates from our reported net sales the impacts of earnings from any acquired or disposed businesses and changes in foreign currency exchange rates. We believe that this measurement is useful to investors as a way to measure and evaluate our underlying commercial operating performance consistently across our segments and the periods presented. This measurement is used by our management for the same reason. Reconciliations to the change in reported net sales, the most directly comparable GAAP financial measure, are included in the section entitled “Results of operations;”
- ***Adjusted EBITDA and Adjusted EBITDA margin***, which are non-GAAP measures discussed in the section entitled “Results of operations.” Adjusted EBITDA is used by investors to measure and evaluate our operating performance exclusive of interest expense, income tax expense, depreciation, amortization and certain other adjustments. Adjusted EBITDA margin is Adjusted EBITDA divided by net sales as determined under GAAP. We believe that these measurements are useful to investors as a way to analyze the underlying trends in our core business consistently across the periods presented. This measurement is used by our management for the same reason. A reconciliation of net income or loss, the most directly comparable GAAP financial measure, to Adjusted EBITDA is included in the section entitled “Reconciliations of non-GAAP measures;”
- ***Cash flows from operating activities***, which we discuss in the section entitled “Liquidity and capital resources—Historical cash flows;”
- ***Free cash flow***, which is a non-GAAP measure, is equal to our cash flow from operating activities, plus acquisition-related costs paid in the period, less capital expenditures. We believe that this measurement is useful to investors as it provides a view on the Company’s ability to generate cash for use in financing or investing activities. This measurement is used by management for the same reason. A reconciliation of cash flows from operating activities, the most directly comparable GAAP financial measure, to free cash flows, is included in the section entitled “Liquidity and capital resources—Historical cash flows.”

### Results of operations

We present results of operations in the same way that we manage our business, evaluate our performance and allocate our resources. We also provide discussion of net sales and Adjusted EBITDA by geographic segment based on customer location: Americas, Europe and AMEA. Corporate costs are managed on a standalone basis and not allocated to segments.

### Executive summary

*(dollars in millions)*

| 2022 | Three months ended March 31, 2021 |  | Change |
| --- | ---: | ---: | ---: |
| Net sales | $1,950.4 | $1,785.6 | $164.8 |
| Gross margin | 35.4% | 34.3% | 110 bps |
| Operating income | $307.0 | $266.3 | $40.7 |
| Net income | 190.4 | 164.0 | 26.4 |
| Adjusted EBITDA | 423.1 | 363.1 | 60.0 |
| Adjusted EBITDA margin | 21.7% | 20.3% | 140 bps |

First quarter net sales were driven by growth in our BioPharma, Healthcare and Advanced Technologies and Applied Materials end markets, as well as the impact of three acquisitions completed in 2021. Commercial excellence, higher volumes in our base business, double-digit growth of our proprietary materials and consumables product group and M&A contributed to expansion in both gross margin and Adjusted EBITDA margin, partially offset by COVID-19 related headwinds.

### Net Sales

#### Three months ended

*(in millions)*

| 2022 | Three months ended March 31, Net sales growth 2021 | Foreign currency impact | Reconciliation of net sales growth to organic net sales growth M&A impact | Organic net sales growth |  |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Americas | $1,143.4 | $1,035.2 | $108.2 | $(1.0) | $47.1 | $62.1 |
| Europe | 680.4 | 650.4 | 30.0 | (39.5) | 52.4 | 17.1 |
| AMEA | 126.6 | 100.0 | 26.6 | (2.8) | 17.7 | 11.7 |
| Total | $1,950.4 | $1,785.6 | $164.8 | $(43.3) | $117.2 | $90.9 |

Net sales increased $164.8 million or 9.2%, which included $43.3 million or 2.5% of unfavorable foreign currency impact and $117.2 million or 6.6% of M&A impact. Organic growth in net sales was $90.9 million or 5.1% and was primarily due to strong growth in our proprietary product and services offerings offsetting approximately 2% COVID-19 related headwinds.

In the Americas, net sales increased $108.2 million or 10.5%, which included $1.0 million or 0.1% of unfavorable foreign currency impact and $47.1 million or 4.6% of M&A impact. Organic growth in net sales was $62.1 million or 6.0%. Additional information on organic net sales growth by end market (with approximate percentage of total organic net sales for the region) is as follows:

- *Biopharma (55%) —* Sales grew high single-digits, with especially strong growth in sales of proprietary materials in biopharma production driven by our serum product offering, partially offset by reduced sales of COVID-19 related products.
- *Healthcare (10%) —* Sales increased high single-digits driven by double-digit growth in our proprietary silicone offerings driven by continued recoveries in the demand for elective surgical procedures.
- *Education and government (15%) —* Sales decreased mid single-digits primarily due to lower purchases of COVID-19 related test kits by university research and government customers. This was partially offset by growth in our K-12 segment as education sales return to pre-pandemic levels.
- *Advanced technologies & applied materials (20%) —* Sales increased high single-digits driven by strong sales to our semiconductor and electronic device customers.

In Europe, net sales increased $30.0 million or 4.6%, which included $39.5 million or 6.1% of unfavorable foreign currency impact and $52.4 million or 8.1% of M&A impact. Organic growth in net sales was $17.1 million or 2.6%. Additional information on organic net sales growth by end market (with approximate percentage of total organic net sales for the region) is follows:

- *Biopharma (50%) —* Sales grew mid single-digits driven by double digit growth in our production chemicals and single use offerings, partially offset by lower sales of COVID-19 related diagnostic testing offerings.
- *Healthcare* (10%) — Sales were flat as double-digit growth from our proprietary silicone offerings was offset by lower sales of of COVID-19 related diagnostic testing offerings.
- *Education & government (10%) —* Sales declined mid single-digits primarily due to COVID-19 related headwinds in the government end market.
- *Advanced technologies & applied materials (30%) —* Sales grew in the mid single-digits driven by strong growth across all customer and product groups.

In AMEA, net sales increased $26.6 million or 26.6%, which included $2.8 million or 2.8% of unfavorable foreign currency impact and $17.7 million or 17.7% of M&A impact. Organic growth in net sales was $11.7 million or 11.7%. Additional information on organic net sales growth by end market (with approximate percentage of total organic net sales for the region) is follows:

- *Biopharma (50%) —* Sales grew low single-digits driven by double-digit growth in biopharma production offset by the completion of certain non-recurring customer R&D projects from the prior year.
- *Advanced technologies & applied materials (40%) —* Sales grew double-digits primarily driven by growth of our proprietary offerings into the semiconductor industry as well as strong industrial demand in the region.

### Gross margin

| 2022 | Three months ended March 31, 2021 |  | Change |
| --- | ---: | ---: | --- |
| Gross margin | 35.4% | 34.3% | 110 bps |

#### Three months ended

Gross margin for the three months ended March 31, 2022 increased 110 basis points, resulting primarily from favorable product mix reflecting higher sales of our proprietary materials and favorable impact from the higher gross margin sales of acquired companies.

### Operating income

*(in millions)*

| 2022 | Three months ended March 31, 2021 |  | Change |
| --- | ---: | ---: | ---: |
| Gross profit | $689.9 | $612.8 | $77.1 |
| Operating expenses | 382.9 | 346.5 | 36.4 |
| Operating income | $307.0 | $266.3 | $40.7 |

#### Three months ended

Operating income increased primarily from higher gross profit, as previously discussed. This was partially offset by higher operating expenses primarily driven by an additional $26.1 million in non-cash amortization expense related to acquisitions as well as investments in our workforce made over the course of 2021 and into 2022.

### Net income

*(in millions)*

| 2022 | Three months ended March 31, 2021 |  | Change |
| --- | ---: | ---: | ---: |
| Operating income | $307.0 | $266.3 | $40.7 |
| Interest expense | (64.8) | (51.5) | (13.3) |
| Loss on extinguishment of debt | (1.8) | (5.2) | 3.4 |
| Other income, net | 1.4 | 1.8 | (0.4) |
| Income tax expense | (51.4) | (47.4) | (4.0) |
| Net income | $190.4 | $164.0 | $26.4 |

#### Three months ended

Net income increased due to higher operating income, as previously discussed. This was partially offset by higher interest expense as a result of incremental debt issued to finance the acquisitions completed in 2021, and increased income tax expense as a result of higher pre-tax income.

### Adjusted EBITDA and Adjusted EBITDA margin

For a reconciliation of Adjusted EBITDA to Net income or loss, the most directly comparable measure under GAAP, see “Reconciliations of non-GAAP financial measures.”

*(dollars in millions)*

| 2022 Adjusted EBITDA: | Three months ended March 31, 2021 |  | Change |
| --- | ---: | ---: | ---: |
| Americas | $294.2 | $252.0 | $42.2 |
| Europe | 143.4 | 131.1 | 12.3 |
| AMEA | 29.3 | 22.6 | 6.7 |
| Corporate | (43.8) | (42.6) | (1.2) |
| Total | $423.1 | $363.1 | $60.0 |
| Adjusted EBITDA margin | 21.7% | 20.3% | 140 bps |

#### Three months ended

Adjusted EBITDA increased $60.0 million or 16.5%, which included a unfavorable foreign currency translation impact of $7.9 million or 2.2% and $45.5 million or 12.5% from M&A. The remaining growth was $22.4 million or 6.2%.

In the Americas, Adjusted EBITDA grew $42.2 million or 16.7%, or 8.5% when adjusted for unfavorable foreign currency translation impact and M&A. Gross margin expansion from commercial excellence and favorable mix related to sales of our higher-margin proprietary products was partially offset by freight expenses, inflationary factors and investments in our workforce made over the course of 2021 and into 2022.

In Europe, Adjusted EBITDA grew $12.3 million or 9.4%, or 1.2% when adjusted for unfavorable foreign currency translation impact and M&A, due to gross margin expansion from favorable mix and commercial excellence offset by freight expenses, non-cash inventory provisions and investments in our workforce made over the course of 2021 and into 2022.

In AMEA, Adjusted EBITDA grew $6.7 million or 29.6%, or 2.5% when adjusted for unfavorable foreign currency translation impact and M&A. The increased sales were offset by unfavorable inflationary factors and freight impacts.

In Corporate, Adjusted EBITDA declined $1.2 million or 2.8% reflecting investments in our workforce made over the course of 2021 and into 2022 and increased stock-based compensation expense.

### Reconciliations of non-GAAP financial measures

The following table presents the reconciliation of net income or loss to Adjusted EBITDA:

*(in millions)*

| 2022 | Three months ended March 31, 2021 |  |
| --- | ---: | ---: |
| Net income | $190.4 | $164.0 |
| Interest expense | 64.8 | 51.5 |
| Income tax expense | 51.4 | 47.4 |
| Depreciation and amortization | 114.5 | 89.0 |
| Loss on extinguishment of debt | 1.8 | 5.2 |
| Net foreign currency loss from financing activities | 0.1 | 0.8 |
| Other stock-based compensation (benefit) expense | (1.3) | 0.6 |
| Acquisition-related expenses | — | 3.0 |
| Integration-related expenses1 | 3.9 | — |
| Purchase accounting adjustments2 | (4.4) | — |
| Restructuring and severance charges3 | 1.9 | 1.6 |
| Adjusted EBITDA | $423.1 | $363.1 |

1\. Represents non-recurring direct costs incurred with third parties to integrate acquired companies. These expenses represent incremental costs and are unrelated to normal operations of our business. Integration expenses are incurred over a pre-defined integration period specific to each acquisition.

2\. Represents the non-cash reduction of contingent consideration related to the Ritter acquisition.

3\. Reflects the incremental expenses incurred in the period related to initiatives to increase profitability and productivity. Typical costs included in this caption are employee severance, site-related exit costs, and contract termination costs.

### Liquidity and capital resources

We fund short-term cash requirements primarily from operating cash flows. Most of our long-term financing is from indebtedness. For the three month period ended March 31, 2022, we generated $152.2 million of cash from operating activities, ended the quarter with $283.6 million of cash and cash equivalents and our availability under credit facilities was $805.5 million. We have no debt repayments due in the next twelve months other than required term loan payments of $38.6 million.

### Liquidity

The following table presents our primary sources of liquidity:

*(in millions)*

| March 31, 2022 Receivables facility Revolving credit facility Total Unused availability under credit facilities: |  |
| --- | ---: |
| Capacity $300.0 $515.0 | $815.0 |
| Undrawn letters of credit outstanding (9.5) — | (9.5) |
| Outstanding borrowings — — | — |
| Unused availability $290.5 $515.0 | $805.5 |
| Cash and cash equivalents | 283.6 |
| Total liquidity | $1,089.1 |

We fund short-term cash requirements primarily from operating cash flows. Some of our credit line availability depends upon maintaining a sufficient borrowing base of eligible accounts receivable. We believe that we have sufficient capital resources to meet our liquidity needs.

Our debt agreements include representations and covenants that we consider usual and customary, and our receivables facility and senior secured credit facilities include a financial covenant that becomes applicable for periods in which we have drawn more than 35% of our revolving credit facility under the senior secured credit facilities. In this circumstance, we are not permitted to have combined borrowings on our senior secured credit facilities and secured notes in excess of a pro forma net leverage ratio, as defined in our credit agreements. As we had not drawn more than 35% of our revolving credit facility in this period, this covenant was not applicable at March 31, 2022.

At March 31, 2022, $242.5 million or 85.5% of our $283.6 million in cash and cash equivalents was held by our non-U.S. subsidiaries and may be subject to certain taxes upon repatriation, primarily where foreign withholding taxes apply.

### Historical cash flows

The following table presents a summary of cash provided by (used in) various activities:

*(in millions)*

| 2022 Operating activities: | Three months ended March 31, 2021 |  | Change |
| --- | ---: | ---: | ---: |
| Net income | $190.4 | $164.0 | 26.4 |
| Non-cash items1 | 123.2 | 114.8 | 8.4 |
| Working capital changes2 | (108.1) | (130.5) | 22.4 |
| All other | (53.3) | (21.4) | (31.9) |
| Total | $152.2 | $126.9 | $25.3 |
| Investing activities | $(39.5) | $(14.6) | $(24.9) |
| Cash paid for acquisitions, net of cash acquired | (15.3) | — | (15.3) |
| Capital expenditures | (24.5) | (15.1) | (9.4) |
| Financing activities | (127.2) | (221.0) | 93.8 |

1\. Consists of typical non-cash charges including depreciation and amortization, stock based compensation expense, deferred income tax expense and others.

2\. Includes changes to our accounts receivable, inventory, contract assets and accounts payable.

Cash flows from operating activities provided $25.3 million more cash in 2022 primarily due to higher net income and favorable working capital changes, offset by higher incentive compensation payments related to fiscal year 2021.

Investing activities used $24.9 million more cash in 2022, reflecting additional cash paid for the acquisition of Masterflex and increased capital spending.

Financing activities used $93.8 million less cash in 2022 primarily due to lower debt repayments in comparison to 2021, offset by fewer proceeds received from the exercise of stock options.

### Free cash flow

*(in millions)*

| 2022 | Three months ended March 31, 2021 |  | Change |
| --- | ---: | ---: | ---: |
| Net cash provided by operating activities | $152.2 | $126.9 | $25.3 |
| Capital expenditures | (24.5) | (15.1) | (9.4) |
| Free cash flow | $127.7 | $111.8 | $15.9 |

Free cash flow was $15.9 million higher in 2022 due to the changes in cash flows from operating activities noted above, partially offset by an increase in capital spending, principally reflecting capacity additions in our global supply chain.

### Indebtedness

For information about our indebtedness, refer to the section entitled “Liquidity” and note 9 to our unaudited condensed consolidated financial statements included in Part I, Item 1 — “Financial statements.”

### New accounting standards

There were no new accounting standards that we expect to have a material impact on our financial position or results of operations upon adoption.

## Controls and procedures

As filed, 1,006 characters.

### Management’s evaluation of disclosure controls and procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)), as of the end of the period covered by this report. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of March 31, 2022, the design and operation of our disclosure controls and procedures were effective to accomplish their objectives at the reasonable assurance level.

### Changes in internal control over financial reporting

There have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934) during the fiscal quarter ended March 31, 2022 that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.

## Risk factors

As filed, 316 characters.

For information regarding factors that could affect the Company's results of operations, financial condition and liquidity, see the risk factors discussed in Part I, Item 1A “Risk Factors” in our Annual Report. There have been no material changes to the risk factors disclosed in Part I—Item 1A of the Annual Report.

Filed Apr 29, 2022.
Source: SEC EDGAR, the filing index for accession 0001722482-22-000114. Last ingested by Listed: Nov 13, 2026, 16:45 ET. No prices; not investment advice.
